Randomized phase II trial comparing amrubicine/irinotecan with cisplatin/irinotecan in patients with extensive-stage small-cell lung cancer: (JMTO LC 08-01) .

Trial Profile

Randomized phase II trial comparing amrubicine/irinotecan with cisplatin/irinotecan in patients with extensive-stage small-cell lung cancer: (JMTO LC 08-01) .

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs Amrubicin (Primary) ; Cisplatin; Irinotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2014 According to the University Hospital Medical Information Network - Japan, status changed from recruiting to active, no longer recruiting.
    • 14 Jul 2012 Additional lead trial centre (Japan-multinational Trial Organization) added as reported by University Hospital Medical Information Network - Japan.
    • 14 Jul 2012 Planned end date changed from 1 Mar 2012 to 31 Mar 2016 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top